Klotho Neurosciences Soars 20% on Debt Elimination

On June 16, 2025, Klotho Neurosciences saw a remarkable 20% surge in pre-market trading, reflecting significant investor confidence and market optimism.

Klotho Neurosciences has successfully raised over $11 million through the exercise of existing warrants by investors over a ten-day period. This capital infusion has been strategically utilized to eliminate all outstanding debt, achieving a debt-free balance sheet. This financial restructuring not only strengthens the company's financial position but also ensures compliance with NASDAQ listing requirements, addressing a critical regulatory concern.

Chardan Capital Markets played a pivotal role as the exclusive financial advisor in this transaction, demonstrating their expertise in facilitating such significant financial maneuvers. The company's proactive approach to debt management and regulatory compliance has positioned it favorably in the market, potentially driving further investor interest and market growth.